Top 5 vaccines by 2020

Print 13 July 2015
FierceVaccnines

Though it picked up some steam in 2014, Prevnar--anticipated to be the world's top shot in 2020--showed some signs of slowing in this year's EvaluatePharma World Preview 2015 report. According to the analysts, the shot--which last year was expected to haul in $6.08 billion in sales, will take in $5.83 billion in 2020. Still, though, enough to make it far and away the world's top vaccine in 5 years.

Last year, EP estimated that Pentacel, Gardasil, Fluzone and Pediarix would round out the top 5, but their estimates have shuffled a bit this year. Now, by 2020, the analysts predict Gardasil to take No. 2 with $2.52 billion in sales; Fluzone in No. 3 with $2.03 billion in sales; Pentacel at No. 4 with $1.68 billion in sales; and Pediarix in the fifth spot with $1.54 in 2020 sales.

All of the shots--minus Gardasil--showed signs of slowing, with the sharpest CAGR drop of 4% in Pentacel's case. Gardasil, last year expected to grow just 2%, is estimated in this year's report to post 4% growth through 2020.

Source

The top 5 vaccines by 2020
Vaccine & Company	Use	2014 Sales (billions)	2020 Sales (billions)	CAGR 2014-20
	Pneumococcal infection	$4.297	$5.83	5%
	Human papillomavirus (HPV)	$2.03	$2.52	4%
	Influenza	$1.72	$2.03	3%
	Diphtheria, pertussis/whooping cough; tetanus; polio; Haemophilus influenzae type B	$1.53	$1.68	2%
	Diphtheria; tetanus; pertussis/whooping cough; hepatitis B; polio	$1.36	$1.54	2%
Courtesy of EvaluatePharma

Return